Avanos Medical (AVNS) Lifted to Outperform at Raymond James
Avanos Medical (NYSE:AVNS) was upgraded by Raymond James from a “market perform” rating to an “outperform” rating in a report issued on Tuesday, The Fly reports.
Several other research firms have also issued reports on AVNS. KeyCorp raised their price target on Avanos Medical from $66.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Morgan Stanley raised their price target on Avanos Medical from $58.00 to $60.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 8th. Finally, Zacks Investment Research upgraded Avanos Medical from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a research report on Thursday, August 9th.
NYSE AVNS opened at $66.05 on Tuesday. The firm has a market capitalization of $3.08 billion, a PE ratio of 28.11 and a beta of 1.60. Avanos Medical has a 52 week low of $41.51 and a 52 week high of $66.30. The company has a quick ratio of 2.18, a current ratio of 2.48 and a debt-to-equity ratio of 0.19.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
Further Reading: Stock Symbol
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.